Bone Diseases (Bone Disease)

04/01/2009 - "Although bisphosphonates have been extremely effective for treating MM bone disease, they do not completely inhibit the development of skeletal events, but only decrease them significantly. "
07/01/2008 - "Contemporary evidence-based studies on the prevalence and impact on quality of life in metastatic bone disease and skeletal-related events, and all major clinical trials describing the efficacy of bisphosphonates for the treatment of metastatic bone disease. "
01/01/2012 - "Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. "
09/01/2010 - "Then, future developments of delivery system of bisphosphonates are also discussed in order to improve their therapeutic efficacy and safety in the treatment of bone diseases."
08/01/2009 - "Currently, bisphosphonates are the mainstay of treatment for myeloma bone disease, although several novel agents appear promising. "

12/01/2004 - "With its favorable efficacy and safety profile, and the added convenience of the oral formulation, ibandronate provides improved treatment options for managing metastatic bone disease."
11/01/2007 - "These results indicate that ibandronate may be an effective treatment for patients with metastatic bone disease following CRC. "
05/01/2004 - "Oral ibandronate is an effective and well-tolerated treatment for metastatic bone disease. "
01/01/2005 - "Efficacy of ibandronate in metastatic bone disease: review of clinical data."
10/01/2010 - "This interim analysis of a prospective non-interventional study documents the efficacy and safety of the amino-bisphosphonate ibandronate in the treatment of metastatic bone disease under real-life conditions. "

05/01/2015 - "Although some studies have reported that vitamin D ameliorates bone disease related to diabetes, the mechanism remains unclear. "
01/01/2015 - "Bone disease, assessed by changes in PTH levels, is improved by all vitamin D preparations. "
01/01/2010 - "Bone disease, assessed by changes in PTH levels, is improved by all vitamin D preparations. "
06/01/2005 - "The current vitamin D requirements in the United States are based on protection against bone diseases. "
07/01/2013 - "New trials evaluating the effects of vitamin D supplementation have failed to reveal any robust clinical benefits beyond its known actions on mineral and bone disease."

09/01/2008 - "A significant interaction was found between dosage of calcium-containing phosphate binders and bone activity such that calcium load had a significantly greater influence on aortic calcifications and stiffening in the presence of adynamic bone disease. "
03/01/2004 - "Studies of calcium metabolism in patients with CKD have shown that adynamic bone disease is a distinct clinical condition that leads to hypercalcaemia via mechanisms different from that seen in high-turnover bone disease. "
10/01/1991 - "By contrast, studies dating from the availability of automated serum calcium measurement found renal stones and hyperparathyroid bone disease in less than 5% of cases, and about half of cases had few or no symptoms. "
02/25/1984 - "Ten normocalcemic patients with advanced metastatic bone disease or myeloma were evaluated in a baseline 20-day calcium balance and kinetic study. "
06/23/1983 - "Ten normocalcemic patients with advanced metastatic bone disease or myeloma were evaluated in a baseline 20-day balance and calcium kinetic study. "

10/01/2005 - "Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. "
03/01/2003 - "A single dose of zoledronic acid was also shown to be effective in preventing the development of osteolytic bone disease. "
02/01/2008 - "Zoledronic acid is the gold standard for the medical management of metastatic bone disease. "
07/01/2010 - "The study was a retrospective audit of 39 consecutive patients with metastatic bone disease secondary to solid tumours who were treated with Zoledronic acid. "
04/01/2001 - "Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. "

01/01/2013 - "Bone tissue-specific tests, such as quantitative analysis of radiographs and serum parathyroid hormone levels, were effective for distinguishing between marmosets with bone disease and those without. "
09/07/1985 - "Transiliac bone biopsy findings improved in four patients with adequate suppression of parathyroid hormone concentrations, deteriorated in two patients who were not compliant, and did not change in five patients in whom initial bone disease was mild. "
01/01/1980 - "(2) decreases levels of immunoreactive parathyroid hormone, and (3) is associated with histologic improvement in bone disease."
06/01/2012 - "The parathormone level seems to be an important agent in influencing bone status, but further studies are needed to understand the other risk factors in kidney-related bone disease."
06/01/2006 - "(6) During clinical trials, 11% of dialysis patients had low parathormone levels, creating a risk of adynamic bone disease and fractures, but available data are sparse. "

11/01/2012 - "Finally, in our experience, pamidronate is effective for improving bone mineral density and safe in patients with intestinal failure-associated bone disease."
01/01/2008 - "It is effective in reducing complications arising from metastatic bone disease in this patient population, with a clinical profile that compares favourably with that of pamidronate. "
06/01/2014 - "Two decades later the C57BL/KaLwRij mouse strain was found to spontaneously develop MM. Testing of pamidronate using this endogenously arising MM model revealed significant reductions in MM-associated bone disease, which was subsequently confirmed in human trials in MM patients. "
01/01/2002 - "The aim of this study was radiographically to monitor the effect of disodium pamidronate on metastatic bone disease, using image-processing techniques. "
07/01/1998 - "We conclude by reviewing the literature on the use of pamidronate in phase II and III trials involving patients with metastatic bone disease. "

01/01/1982 - "Treatment with 1 alpha-OH D3 produces radiological improvement in the majority of patients with dialysis bone disease, but the lack of correlation with histological changes confirms the need for regular radiographic examination. "
01/01/2009 - "Thus, our study may provide a molecular basis for the treatment of human bone diseases by 1alpha,25(OH)(2)D(3) through regulation of the IFN-beta and NFATc1 axis."
06/01/1996 - "Therefore, we undertook a placebo-controlled trial of 24,25(OH)2 D3 supplementation to standard treatment in patients with XLH to improve bone disease and reduce hyperparathyroid complications. "
01/01/2014 - "The logistic model reported low levels of 25(OH)D3 to be a significant predictor of bone disease [odds ratio=2.66(6.8), p < 0.009]. "
07/01/2007 - "The 1,25(OH)2VD was significantly higher in the patients with Grade I to III bone disorder compared to the patients with normal bones or early bone disease. "

08/01/1990 - "[Experimental study of the mechanism of aluminum-induced bone disease]."
01/01/1988 - "The study outlines the metabolism of aluminum, the pathogenesis, prevalence, morbidity and mortality of aluminum-related bone disease, the histopathology of bone with aluminum accumulation, the recognized difficulties inherent in the diagnosis of aluminum-related bone disease, and the current understanding as relates to prevention and therapy."
01/01/1988 - "This editorial presents an overview of the most recent investigations of aluminum accumulation in humans, experimental animal models, and at the cellular level, presents the metabolic relationships known to exist as well as those strongly suggested in documented studies, and identifies those aspects of aluminum-related bone disease awaiting study in this increasingly important field of inquiry. "
12/01/1987 - "In the present study we attempted treatment of the aluminum-related bone disease with DFO, a potent chelating agent. "
02/01/1986 - "Experimental aluminum-induced bone disease: studies in vivo."

11/01/2007 - "The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease."
01/01/1991 - "A review is made of 126 publications on clinical studies concerning the use of clodronate in the therapy of bone disease involving 1930 patients in order to evaluate the tolerability and the effects following the short-and long-term administration of this drug. "
01/01/1989 - "The results of this prospective pilot trial indicate that supportive long-term treatment with parenteral Clodronate can contribute significantly to controlling the progression of myeloma bone disease."
07/01/2014 - "Both clodronate and bioactive glass are mostly used alone as treatment in various bone diseases but, they are also known to have beneficial effects in dental application. "
11/01/2007 - "There were 125 patients with metastatic bone disease randomized to daily oral clodronate (800, 1,600, 2,400 and 3,200 mg) or placebo in a double-blind, multicenter study. "

04/01/1991 - "Total parathyroidectomy without an autograft was performed in nine dialysis patients without any short-term adverse effects, and with clinical and pathological improvement in bone disease. "
09/01/2013 - "Bone disease: preparing for your parathyroidectomy."
06/01/2010 - "In the studied series of total parathyroidectomy without autoimplant, adynamic bone disease occurred in three out of seven repeat bone biopsies while improvement occurred in the rest. "
10/01/2008 - "To define the scope of bone disease among men referred for parathyroidectomy and to document bone density screening trends in this high-risk population. "
12/01/2003 - "Bone disease was present in 32 patients (88.9%), with parathyroidectomy being more frequently performed in the PD patients (p = 0.048). "

11/01/2005 - "The objective of the study was to determine the situation concerning mineral metabolism and bone disease in hemodialysis (HD) patients living in the community of Valencia (Spain), as well as the clinical practices for bone disease control in relation to the laboratory targets recommended in the National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) guidelines. "
07/01/2004 - "However, subsequent studies using the Scantibodies assay have failed to better predict the underlying bone disease in adults undergoing maintenance hemodialysis. "
09/01/2014 - "There is a paucity of data on mineral bone disease in maintenance hemodialysis (MHD) patients from India. "
09/01/2014 - "Mineral bone disease in maintenance hemodialysis patients: Association with morbidity and mortality."
01/01/2014 - "The full spectrum of hemodialysis was covered with plenary lectures and symposiums delivered by experts from different subspecialties in nephrology starting from the history of hemodialysis, mineral bone disease, microinflammation and advanced techniques in hemodialysis. "

01/01/2009 - "Translational medicine or research, an emerging discipline on the frontier of basic science and medical practice, has the potential to enhance the speed and efficiency of the drug development process through the utilization of pharmacogenetics and pharmacogenomics. Pharmacogenetics is the study of genetic causes of individual variations in drug response whereas pharmacogenomics deals with the simultaneous impact of multiple mutations in the genome that may determine the patient's response to drug therapy. The utilization of these methods in the drug development process may therefore identify patient sub-populations that exhibit more effective responses and/or an improved benefit/risk profile upon treatment. The authors provide examples of the use of pharmacogenetics and pharmacogenomics in the fields of cardiovascular, pulmonary, oncological, and bone diseases and also highlight the potential economic value of their development."
11/01/2015 - "Recent advances in drug therapy for metastatic bone diseases are changing the indications for surgicaltreatments. "
07/01/2014 - "The results support the concept that chemotherapy may not be necessary for limited bone disease. "
06/01/2014 - "Myeloma bone disease represents a threefold therapeutic problem: (i) per se because of the associated morbidity, mortality and the accompanying decrease of quality of life, (ii) as survival space for (residual) myeloma cells after primarily successful chemotherapy and subsequently necessary chemotherapeutic treatment, and (iii) the occurrence of bone lesions in asymptomatic patients is the most common cause for the initiation of treatment to avoid myeloma-induced fractures. "
08/15/2013 - "Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors."

01/01/2014 - "Following transplantation (Tx), improvement in CV disease has been reported; however, data regarding changes in bone disease remain controversial. "
10/01/2009 - "Evolution of bone disease at 2 years after transplantation: a single-center study."
04/01/2005 - "This study was conducted to assess the evidence available to guide targeted treatment to reduce bone disease in transplant recipients. "
04/01/2005 - "Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials."
06/01/2003 - "Short-term studies after transplantation have shown that many patients exhibit a pattern consistent with adynamic bone disease. "

01/01/1992 - "Studies of selected patients have indicated that Al-related bone disease ameliorates after successful kidney transplantation, but systematic studies of bone Al have not been reported. "
07/01/2012 - "Low turnover bone disease occurs more frequently after kidney transplantation according to bone biopsy studies. "
12/01/2007 - "The aim of this study was to investigate frequency and histomorphometric pattern of bone disease after renal transplantation. "
04/01/2005 - "With increasing survival after renal transplantation, this study stresses the importance of randomized controlled trial evidence of interventions of bone disease after renal transplantation."
04/01/2005 - "The Cochrane CENTRAL Registry, MEDLINE, and EMBASE were searched for randomized trials of interventions for bone disease after renal transplantation. "